{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:11:41Z","timestamp":1785507101628,"version":"3.56.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00705-020-04768-3","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T19:04:05Z","timestamp":1597086245000},"page":"2419-2438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Potential strategies for combating COVID-19"],"prefix":"10.1007","volume":"165","author":[{"given":"Saba","family":"Shamim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelal Jaber","family":"Kharaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5649-5768","authenticated-orcid":false,"given":"Ghulam","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"3","key":"4768_CR1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/v11030210","volume":"11","author":"Y Fan","year":"2019","unstructured":"Fan Y, Zhao K, Shi Z-L, Zhou P (2019) Bat coronaviruses in China. Viruses 11(3):210","journal-title":"Viruses"},{"key":"4768_CR2","first-page":"85","volume-title":"Coronaviruses: a comparative review","author":"K McIntosh","year":"1974","unstructured":"McIntosh K (1974) Coronaviruses: a comparative review. Springer, Berlin, Heidelberg, pp 85\u2013129"},{"key":"4768_CR3","unstructured":"King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (2012) Virus taxonomy: classification and nomenclature of viruses. Ninth report of the International Committee on Taxonomy of Viruses. Academic Press, London, Waltham"},{"issue":"1","key":"4768_CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2334-10-50","volume":"10","author":"EH Lau","year":"2010","unstructured":"Lau EH, Hsiung CA, Cowling BJ, Chen C-H, Ho L-M, Tsang T, Chang C-W, Donnelly CA, Leung GM (2010) A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. BMC Infect Dis 10(1):50","journal-title":"BMC Infect Dis"},{"issue":"16","key":"4768_CR5","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/JVI.00080-16","volume":"90","author":"NR Sexton","year":"2016","unstructured":"Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR (2016) Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90(16):7415\u20137428","journal-title":"J Virol"},{"key":"4768_CR6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2014the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264","journal-title":"Int J Infect Dis"},{"key":"4768_CR7","doi-asserted-by":"crossref","unstructured":"Korsman SN, van Zyl GU, Loiuse N, Anderson MI, Preiser W (2012) Human coronaviruses, vol 9. Churchill Livingstone","DOI":"10.1016\/B978-0-443-07367-0.00038-0"},{"issue":"4","key":"4768_CR8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2213-2600(20)30110-7","volume":"8","author":"SA \u00d1amendys-Silva","year":"2020","unstructured":"\u00d1amendys-Silva SA (2020) Respiratory support for patients with COVID-19 infection. Lancet Respir Med 8(4):e18","journal-title":"Lancet Respir Med"},{"issue":"10223","key":"4768_CR9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395(10223):470\u2013473","journal-title":"Lancet"},{"issue":"11","key":"4768_CR10","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","volume":"24","author":"JS Kahn","year":"2005","unstructured":"Kahn JS, McIntosh K (2005) History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24(11):S223\u2013S227","journal-title":"Pediatr Infect Dis J"},{"key":"4768_CR11","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1097\/CCM.0000000000003842","volume":"47","author":"Y Song","year":"2019","unstructured":"Song Y, Yao C, Yao Y et al. (2019) XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med 47:e735\u2013e743","journal-title":"Crit Care Med"},{"issue":"10","key":"4768_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.7150\/ijbs.45538","volume":"16","author":"Y Yang","year":"2020","unstructured":"Yang Y, Islam MS, Wang J, Li Y, Chen X (2020) Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 16(10):1708\u20131717. https:\/\/doi.org\/10.7150\/ijbs.45538","journal-title":"Int J Biol Sci"},{"key":"4768_CR13","doi-asserted-by":"crossref","unstructured":"Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (2020) COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines Immunother 2020:1\u20137","DOI":"10.1080\/21645515.2020.1735227"},{"key":"4768_CR14","unstructured":"Epidemic response group ups coronavirus vaccine funding to $23.7 million. https:\/\/www.reuters.com\/article\/us-health-coronavirus-vaccines-cepi\/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO. Retrieved 21 Mar 2020"},{"key":"4768_CR15","unstructured":"Canada to spend $192M on developing COVID-19 vaccine. https:\/\/globalnews.ca\/news\/6717883\/coronavirus-canada-vaccine-spending\/. Retrieved 24 Mar 2020"},{"issue":"60","key":"4768_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.12688\/wellcomeopenres.15821.1","volume":"5","author":"BJ Maguire","year":"2020","unstructured":"Maguire BJ, Gu\u00e9rin PJ (2020) A living systematic review protocol for COVID-19 clinical trial registrations. Wellcome Open Res 5(60):60","journal-title":"Wellcome Open Res"},{"key":"4768_CR17","unstructured":"The Drug Development Process. https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/drug-development-process. Retrieved 21 Mar 2020"},{"key":"4768_CR18","unstructured":"Why will a coronavirus vaccine take so long? https:\/\/www.bostonglobe.com\/2020\/03\/19\/opinion\/why-will-coronavirus-vaccine-take-so-long\/. Retrieved 21 Mar 2020"},{"key":"4768_CR19","unstructured":"About the Innovative Medicines Initiative. https:\/\/www.imi.europa.eu\/about-imi. Retrieved 24 Jan 2020"},{"key":"4768_CR20","unstructured":"Critical Path Initiative. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/critical-path-initiative. Retrieved 24 Jan 2020"},{"key":"4768_CR21","unstructured":"Breakthrough Therapy. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy. Retrieved 24 Jan. 2020"},{"key":"4768_CR22","unstructured":"SARS-CoV-2 Diagnostic Pipeline. https:\/\/www.finddx.org\/covid-19\/pipeline\/. Retrieved 12 Apr 2020"},{"issue":"10233","key":"4768_CR23","doi-asserted-by":"publisher","first-page":"P1322","DOI":"10.1016\/S0140-6736(20)30798-4","volume":"395","author":"M Cattani","year":"2020","unstructured":"Cattani M (2020) Global coalition to accelerate COVID-19 clinical research in resource-limited settings. Lancet 395(10233):P1322\u2013P1325. https:\/\/doi.org\/10.1016\/S0140-6736(20)30798-4","journal-title":"Lancet"},{"key":"4768_CR24","unstructured":"COVID-19 treatment and vaccine tracker. https:\/\/milkeninstitute.org\/sites\/default\/files\/2020-04\/Covid19%2520Tracker%2520NEW4-3-20-2.pdf. Retrieved 3 Apr 2020"},{"key":"4768_CR25","volume-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group, Berlin"},{"key":"4768_CR26","unstructured":"First up for COVID-19: nearly 30 clinical readouts before end of April [https:\/\/www.biocentury.com\/article\/304658\/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months. Retrieved 10 Apr 2020"},{"key":"4768_CR27","unstructured":"Severe acute respiratory syndrome (SARS). https:\/\/www.cdc.gov\/sars\/. Retrieved 10 Apr 2020"},{"issue":"1","key":"4768_CR28","first-page":"1","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38(1):1\u20139","journal-title":"Asian Pac J Allergy Immunol"},{"key":"4768_CR29","unstructured":"Middle East Respiratory Syndrome (MERS). https:\/\/www.cdc.gov\/coronavirus\/mers\/index.html. Retrieved 12 Apr 2020"},{"issue":"9399","key":"4768_CR30","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","volume":"362","author":"W Gao","year":"2003","unstructured":"Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A (2003) Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362(9399):1895\u20131896","journal-title":"Lancet"},{"issue":"45","key":"4768_CR31","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","volume":"32","author":"E Kim","year":"2014","unstructured":"Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A (2014) Immunogenicity of an adenoviral-based middle east respiratory syndrome coronavirus vaccine in BALB\/c mice. Vaccine 32(45):5975\u20135982","journal-title":"Vaccine"},{"issue":"1","key":"4768_CR32","doi-asserted-by":"crossref","first-page":"01","DOI":"10.2217\/fvl.12.126","volume":"8","author":"S Jiang","year":"2013","unstructured":"Jiang S, Lu L, Du L (2013) Development of SARS vaccines and therapeutics is still needed. Future Virol 8(1):01","journal-title":"Future Virol"},{"key":"4768_CR33","unstructured":"SARS (severe acute respiratory syndrome). https:\/\/www.nhs.uk\/conditions\/sars\/. Retrieved 12 Apr 2020"},{"key":"4768_CR34","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","volume":"10","author":"CY Yong","year":"2019","unstructured":"Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019) Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front Microbiol 10:1781","journal-title":"Front Microbiol"},{"key":"4768_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMe2002387","volume":"382","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC, Redield RR (2020) Covid-19\u2014navigating the uncharted. N Engl J Med 382:1268\u20131269. https:\/\/doi.org\/10.1056\/NEJMe2002387","journal-title":"N Engl J Med"},{"key":"4768_CR36","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1056\/NEJMp2003762","volume":"382","author":"B Gates","year":"2020","unstructured":"Gates B (2020) Responding to Covid-19\u2014a once-in-a-century pandemic? N Engl J Med 382:1677\u20131679. https:\/\/doi.org\/10.1056\/NEJMp2003762","journal-title":"N Engl J Med"},{"key":"4768_CR37","unstructured":"With Wuhan virus genetic code in hand, scientists begin work on a vaccine. https:\/\/www.reuters.com\/article\/us-china-health-vaccines-idUSKBN1ZN2J8. Retrieved 11 Apr 2020"},{"key":"4768_CR38","unstructured":"These 21 companies are working on coronavirus treatments or vaccines\u2014here\u2019s where things stand. https:\/\/www.marketwatch.com\/story\/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06. Retrieved 10 Apr 2020"},{"key":"4768_CR39","unstructured":"Coronavirus treatment: vaccines\/drugs in the pipeline for COVID-19. https:\/\/www.clinicaltrialsarena.com\/analysis\/coronavirus-mers-cov-drugs\/. Retrieved 11 Apr 2020"},{"key":"4768_CR40","unstructured":"Increasing number of biopharma drugs target COVID-19 as virus spreads. https:\/\/www.bioworld.com\/articles\/433331-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads. Retrieved 10 Apr 2020"},{"key":"4768_CR41","unstructured":"Draft landscape of COVID-19 candidate vaccine. https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf. Retrieved 11 Apr 2020"},{"key":"4768_CR42","unstructured":"NIH clinical trial of investigational vaccine for COVID-19 begins. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-investigational-vaccine-covid-19-begins. Retrieved 12 Apr 2020"},{"key":"4768_CR43","unstructured":"China approves first homegrown COVID-19 vaccine to enter clinical trials. https:\/\/www.bioworld.com\/articles\/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials. Retrieved 12 Apr 2020"},{"key":"4768_CR44","unstructured":"Coronavirus Drug Update (2020) The latest info on pharmaceutical treatments and vaccines. https:\/\/www.forbes.com\/sites\/alexknapp\/2020\/03\/13\/coronavirus-drug-update-the-latest-info-on-pharmaceutical-treatments-and-vaccines\/#2ea04c8521db. Retrieved 12 Apr 2020"},{"key":"4768_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8497","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt K, Cohen J (2020) WHO launches global megatrial of the four most promising coronavirus treatments. Science. https:\/\/doi.org\/10.1126\/science.abb8497","journal-title":"Science"},{"key":"4768_CR46","unstructured":"Government of Canada funds 49 additional COVID-19 research projects\u2014details of the funded projects. https:\/\/www.canada.ca\/en\/institutes-health-research\/news\/2020\/03\/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html. Retrieved 12 Apr 2020"},{"key":"4768_CR47","unstructured":"Information for clinicians on therapeutic options for COVID-19 patients. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/therapeutic-options.html. Updated April 7 2020, Retrieved 12 Apr 2020"},{"issue":"5","key":"4768_CR48","doi-asserted-by":"publisher","first-page":"E639","DOI":"10.1016\/S2214-109X(20)30114-5","volume":"8","author":"O Mitj\u00e0","year":"2020","unstructured":"Mitj\u00e0 O, Clotet B (2020) Use of antiviral drugs to reduce COVID-19 transmission. Lancet Global Health 8(5):E639\u2013E640. https:\/\/doi.org\/10.1016\/S2214-109X(20)30114-5","journal-title":"Lancet Global Health"},{"key":"4768_CR49","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M (2020) A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. New Engl J Med 382:1787\u20131799","journal-title":"New Engl J Med"},{"issue":"4","key":"4768_CR50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38(4):379\u2013381","journal-title":"Nat Biotechnol"},{"key":"4768_CR51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","volume":"9","author":"RL Kruse","year":"2020","unstructured":"Kruse RL (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9:72","journal-title":"F1000Res"},{"key":"4768_CR52","unstructured":"UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment. https:\/\/news.un.org\/en\/story\/2020\/03\/1059722. Retrieved 12 Apr 2020"},{"issue":"6485","key":"4768_CR53","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","volume":"367","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science 367(6485):1412\u20131413","journal-title":"Science"},{"issue":"15","key":"4768_CR54","doi-asserted-by":"crossref","first-page":"E405","DOI":"10.1503\/cmaj.200438","volume":"192","author":"MP Cheng","year":"2020","unstructured":"Cheng MP, Lee TCL, Tan DH, Murthy S (2020) Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. CMAJ 192(15):E405\u2013E407","journal-title":"CMAJ"},{"key":"4768_CR55","unstructured":"WHO to launch multinational trial to jumpstart search for coronavirus drugs. https:\/\/www.statnews.com\/2020\/03\/18\/who-to-launch-multinational-trial-to-jumpstart-search-for-coronavirus-drugs\/. Retrieved 12 Apr 2020"},{"key":"4768_CR56","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19-27 March 2020. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---27-march-2020. Retrieved 10 Apr 2020"},{"key":"4768_CR57","unstructured":"Gilead's coronavirus treatment is barreling its way into new clinical trials. https:\/\/fortune.com\/2020\/02\/26\/gilead-coronavirus-treatment-clinical-trials-remdesivir\/. Retrieved 12 Apr 2020"},{"issue":"5","key":"4768_CR58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","volume":"92","author":"L Zhang","year":"2020","unstructured":"Zhang L, Liu Y (2020) Potential interventions for novel coronavirus in China: a systemic review. J Med Virol 92(5):479\u2013490","journal-title":"J Med Virol"},{"key":"4768_CR59","unstructured":"Coronavirus: Japanese anti-viral drug effective in treating patients, Chinese official says. https:\/\/www.independent.co.uk\/news\/world\/asia\/coronavirus-treatment-anti-viral-drug-favipiravir-avigan-wuhan-china-a9408066.html. Retrieved 10 Apr 2020"},{"key":"4768_CR60","unstructured":"FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia. https:\/\/www.cancernetwork.com\/news\/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia. Retrieved 11 Apr 2020"},{"key":"4768_CR61","unstructured":"Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. https:\/\/www.fda.gov\/media\/136534\/download. Retrieved 12 Apr 2020"},{"key":"4768_CR62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the eicacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279\u2013283","journal-title":"J Crit Care"},{"key":"4768_CR63","doi-asserted-by":"crossref","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72\u201373 (PubMed PMID: 32074550. In.: Epub 2020\/02\/20. eng; 2020)","DOI":"10.5582\/bst.2020.01047"},{"issue":"10","key":"4768_CR64","first-page":"1001","volume":"2020","author":"Z Jie","year":"2020","unstructured":"Jie Z, He H, Xi H, Zhi Z (2020) Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert Consens Chloroquine Phosphate Treat Novel Coronavirus Pneumonia [in Chinese] 2020(10):1001\u20131939","journal-title":"Expert Consens Chloroquine Phosphate Treat Novel Coronavirus Pneumonia [in Chinese]"},{"key":"4768_CR65","unstructured":"Physicians work out treatment guidelines for coronavirus. https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=7428. Retrieved 12 Apr 2020"},{"key":"4768_CR66","unstructured":"Plaquenil (hydroxychloroquine sulfate) dose, indications, adverse effects, interactions. https:\/\/www.pdr.net\/drug-summary\/Plaquenil-hydroxychloroquine-sulfate-1911. Retrieved 12 Apr 2020"},{"issue":"15","key":"4768_CR67","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71(15):732\u2013739","journal-title":"Clin Infect Dis"},{"key":"4768_CR68","doi-asserted-by":"crossref","unstructured":"Van Norman GA (2019) Phase II trials in drug development and adaptive trial design. JACC Basic Transl Sci 4(3):428\u2013437","DOI":"10.1016\/j.jacbts.2019.02.005"},{"key":"4768_CR69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 11:156\u2013164","journal-title":"Contemp Clin Trials Commun"},{"key":"4768_CR70","unstructured":"Vaccine testing and the approval process. https:\/\/www.cdc.gov\/vaccines\/basics\/test-approve.html. Retrieved 12 Apr 2020"},{"key":"4768_CR71","unstructured":"Step 2: Preclinical Research. https:\/\/www.fda.gov\/patients\/drug-development-process\/step-2-preclinical-research. Retrieved 10 Apr 2020"},{"key":"4768_CR72","unstructured":"Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time? https:\/\/www.statnews.com\/2020\/03\/19\/coronavirus-antibody-therapies-will-they-be-ready-in-time\/. Retrieved 12 Apr 2020"},{"key":"4768_CR73","unstructured":"Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus. https:\/\/www.sciencealert.com\/who-says-a-coronavirus-vaccine-is-18-months-away. Retrieved 12 Apr 2020"},{"key":"4768_CR74","unstructured":"When will a coronavirus vaccine be ready? https:\/\/www.theguardian.com\/world\/2020\/apr\/06\/when-will-coronavirus-vaccine-be-ready. Retrieved 10 Apr 2020"},{"key":"4768_CR75","unstructured":"Clinical development success rates: 2006\u20132015. https:\/\/www.bio.org\/sites\/default\/files\/legacy\/bioorg\/docs\/Clinical%2520Development%2520Success%2520Rates%25202006-2015%2520-%2520BIO,%2520Biomedtracker,%2520Amplion%25202016.pdf. Retrieved 10 Apr 2020"},{"key":"4768_CR76","unstructured":"Trial drug can significantly block early stages of COVID-19 in engineered human tissues. https:\/\/www.eurekalert.org\/pub_releases\/2020-04\/uobc-tdc040220.php. Retrieved 12 Apr 2020"},{"issue":"4","key":"4768_CR77","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905\u2013913.e7","journal-title":"Cell"},{"issue":"6489","key":"4768_CR78","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020) Crystal structure of SARSCoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368(6489):409\u2013412","journal-title":"Science"},{"issue":"1","key":"4768_CR79","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14(1):58\u201360","journal-title":"Drug Discov Ther"},{"issue":"3","key":"4768_CR80","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269\u2013271","journal-title":"Cell Res"},{"key":"4768_CR81","doi-asserted-by":"crossref","unstructured":"Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M (2020) The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem AC120:013056","DOI":"10.1074\/jbc.AC120.013056"},{"key":"4768_CR82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"T Sheahan","year":"2020","unstructured":"Sheahan T, Sims A, Leist S, Sch\u00e4fer A, Won J, Brown A, Montgomery S, Hogg A, Babusis D, Clarke M (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222","journal-title":"Nat Commun"},{"issue":"396","key":"4768_CR83","doi-asserted-by":"crossref","first-page":"EAAL3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB et al (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9(396):EAAL3653","journal-title":"Sci Transl Med"},{"issue":"2","key":"4768_CR84","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9(2):e00221\u2013e1218","journal-title":"MBio"},{"issue":"5","key":"4768_CR85","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L et al (2017) Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem 60(5):1648\u20131661","journal-title":"J Med Chem"},{"issue":"7594","key":"4768_CR86","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531(7594):381\u2013385","journal-title":"Nature"},{"issue":"24","key":"4768_CR87","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A (2019) A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381(24):2293\u20132303","journal-title":"N Engl J Med"},{"issue":"10","key":"4768_CR88","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929\u2013936","journal-title":"N Engl J Med"},{"issue":"10043","key":"4768_CR89","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","volume":"388","author":"M Jacobs","year":"2016","unstructured":"Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388(10043):498\u2013503","journal-title":"Lancet"},{"issue":"2","key":"4768_CR90","first-page":"171","volume":"215","author":"J D\u00f6rnemann","year":"2017","unstructured":"D\u00f6rnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H, Van Herp M, Koli\u00e9 M-C, Yosifiva V, Caluwaerts S, McElroy AK (2017) First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis 215(2):171\u2013174","journal-title":"J Infect Dis"},{"key":"4768_CR91","unstructured":"First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.09.20032896v1.full.pdf. Retrieved 14 Mar 2020"},{"issue":"4","key":"4768_CR92","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55(4):105932","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"4768_CR93","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","volume":"49","author":"C Biot","year":"2006","unstructured":"Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E (2006) Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 49(9):2845\u20132849","journal-title":"J Med Chem"},{"issue":"5","key":"4768_CR94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-199325050-00005","volume":"25","author":"SE Tett","year":"1993","unstructured":"Tett SE (1993) Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 25(5):392\u2013407","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4768_CR95","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56(1):105949","journal-title":"Int J Antimicrob Agents"},{"key":"4768_CR96","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762","journal-title":"Antiviral Res"},{"issue":"42","key":"4768_CR97","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, Chaudhuri R, Fu W, Prabhakar BS, Johnson ME (2008) A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci 105(42):16119\u201316124","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"4768_CR98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"C Chu","year":"2004","unstructured":"Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, Kao R, Poon L, Wong C, Guan Y (2004) Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3):252\u2013256","journal-title":"Thorax"},{"issue":"8","key":"4768_CR99","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58(8):4875\u20134884","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4768_CR100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FTD.0b013e31822d578b","volume":"33","author":"EL Aspiroz","year":"2011","unstructured":"Aspiroz EL, Buelga DS, Figueroa SC, Galera RML, Pascuet ER (2011) Hurl\u00e9 AD-G, S\u00e1nchez MJG: Population pharmacokinetics of lopinavir\/ritonavir (Kaletra) in HIV-infected patients. Ther Drug Monit 33(5):573\u2013582","journal-title":"Ther Drug Monit"},{"key":"4768_CR101","doi-asserted-by":"crossref","unstructured":"Chan JF-W, Yao Y, Yeung M-L, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P (2015) Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212(12):1904\u20131913","DOI":"10.1093\/infdis\/jiv392"},{"issue":"1","key":"4768_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3906-2","volume":"21","author":"YM Arabi","year":"2020","unstructured":"Arabi YM, Asiri AY, Assiri AM, Jokhdar HAA, Alothman A, Balkhy HH, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M (2020) Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 21(1):1\u20138","journal-title":"Trials"},{"issue":"6","key":"4768_CR103","first-page":"399","volume":"9","author":"T Que","year":"2003","unstructured":"Que T, Wong V, Yuen K (2003) Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9(6):399\u2013406","journal-title":"Hong Kong Med J"},{"key":"4768_CR104","unstructured":"The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection, 7th edn. https:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-03\/04\/content_5486705.html. Accessed 6 Mar 2020"},{"issue":"15","key":"4768_CR105","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","volume":"323","author":"BE Young","year":"2020","unstructured":"Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J et al (2020) Epidemiologic features and clinical course of patients infected with SARSCoV-2 in Singapore. JAMA 323(15):1488\u20131494","journal-title":"JAMA"},{"issue":"6","key":"4768_CR106","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.3346\/jkms.2020.35.e79","volume":"35","author":"J Lim","year":"2020","unstructured":"Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, Choe K-W, Kang YM, Lee B, Park S-J (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RTPCR. J Korean Med Sci 35(6):E79","journal-title":"J Korean Med Sci"},{"issue":"5","key":"4768_CR107","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jmv.25711","volume":"92","author":"W Han","year":"2020","unstructured":"Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, Wu Q, Fang F, Cheng L, Jiao N, Li X, Chen Q (2020) The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol 92(5):461\u2013463","journal-title":"J Med Virol"},{"issue":"1","key":"4768_CR108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","volume":"14","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen X, Lu Y, Chen F, Zhang W (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14(1):64\u201368","journal-title":"Biosci Trends"},{"issue":"11","key":"4768_CR109","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. JAMA 323(11):1061\u20131069","journal-title":"JAMA"},{"issue":"10223","key":"4768_CR110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513","journal-title":"Lancet"},{"issue":"10229","key":"4768_CR111","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054\u20131062","journal-title":"Lancet"},{"issue":"4","key":"4768_CR112","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAI.0b013e318232b057","volume":"58","author":"BM Best","year":"2011","unstructured":"Best BM, Capparelli EV, Diep H, Rossi SS, Farrell MJ, Williams E, Lee G, van den Anker JN, Rakhmanina N (2011) Pharmacokinetics of lopinavir\/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 58(4):385","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"4768_CR113","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","volume":"9","author":"J-F Rossignol","year":"2016","unstructured":"Rossignol J-F (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9(3):227\u2013230","journal-title":"J Infect Public Health"},{"issue":"7","key":"4768_CR114","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","volume":"14","author":"J Haffizulla","year":"2014","unstructured":"Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol J (2014) Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis 14(7):609\u2013618","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"4768_CR115","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciz100","volume":"69","author":"AE Gami\u00f1o-Arroyo","year":"2019","unstructured":"Gami\u00f1o-Arroyo AE, Guerrero ML, McCarthy S, Ram\u00edrez-Venegas A, Llamosas-Gallardo B, Galindo-Fraga A, Moreno-Espinosa S, Rold\u00e1n-Arag\u00f3n Y, Araujo-Mel\u00e9ndez J, Hunsberger S (2019) Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis 69(11):1903\u20131911","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4768_CR116","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15(8):813\u2013822","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"4768_CR117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"4768_CR118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK (2018) Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis 67(4):533\u2013540","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4768_CR119","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23(8):943","journal-title":"Oncologist"},{"issue":"00026","key":"4768_CR120","first-page":"v1","volume":"202003","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X (2020) Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 202003(00026):v1","journal-title":"ChinaXiv"},{"issue":"9","key":"4768_CR121","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3(9):E343","journal-title":"PLoS Med"},{"issue":"6","key":"4768_CR122","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","volume":"129","author":"R-c Chen","year":"2006","unstructured":"Chen R-c, Tang X-p, Tan S-y, Liang B-l, Wan Z-y, Fang J-q, Zhong N (2006) Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 129(6):1441\u20131452","journal-title":"Chest"},{"issue":"4","key":"4768_CR123","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","volume":"31","author":"N Lee","year":"2004","unstructured":"Lee N, Chan KA, Hui DS, Ng EK, Wu A, Chiu RW, Wong VW, Chan PK, Wong K, Wong E (2004) Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31(4):304\u2013309","journal-title":"J Clin Virol"},{"issue":"2","key":"4768_CR124","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinf.2004.09.008","volume":"51","author":"TW Auyeung","year":"2005","unstructured":"Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, Li PC, Lok KH, Ng YY, Wong WM (2005) The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 51(2):98\u2013102","journal-title":"J Infect"},{"issue":"6","key":"4768_CR125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A (2018) Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197(6):757\u2013767","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4768_CR126","first-page":"1","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180(7):1\u201311","journal-title":"JAMA Intern Med"},{"issue":"10225","key":"4768_CR127","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"L Shang","year":"2020","unstructured":"Shang L, Zhao J, Hu Y, Du R, Cao B (2020) On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395(10225):683\u2013684","journal-title":"Lancet"},{"issue":"21","key":"4768_CR128","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1001\/jama.289.21.JOC30885","volume":"289","author":"CM Booth","year":"2003","unstructured":"Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P (2003) Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289(21):2801\u20132809","journal-title":"JAMA"},{"issue":"20","key":"4768_CR129","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","volume":"348","author":"N Lee","year":"2003","unstructured":"Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung C, To K (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348(20):1986\u20131994","journal-title":"N Engl J Med"},{"issue":"4","key":"4768_CR130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","volume":"10","author":"EL Tan","year":"2004","unstructured":"Tan EL, Ooi EE, Lin C-Y, Tan HC, Ling AE, Lim B, Stanton LW (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10(4):581","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"4768_CR131","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","volume":"70","author":"YM Arabi","year":"2019","unstructured":"Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, Almotairi A, Al Khatib K (2019) Ribavirin and interferon therapy for critically Ill patients with middle east respiratory syndrome: a multicenter observational study. Clin infect Dis 70(9):1837\u20131844","journal-title":"Clin infect Dis"},{"key":"4768_CR132","unstructured":"Nitric oxide investigated as COVID-19 Treatment. https:\/\/www.webmd.com\/lung\/news\/20200409\/nitric-oxide-investigated-as-covid19-treatment. Retrieved 10 Apr 2020"},{"issue":"1","key":"4768_CR133","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","volume":"21","author":"A Casadevall","year":"1995","unstructured":"Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 21(1):150\u2013161","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4768_CR134","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski A (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2(9):695\u2013703","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"4768_CR135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","volume":"77","author":"JS Zhang","year":"2005","unstructured":"Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, Wang X, Ning Y, Liu YF, Gao Q (2005) A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 77(2):147\u2013150","journal-title":"J Med Virol"},{"issue":"4","key":"4768_CR136","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","volume":"18","author":"JH Beigel","year":"2018","unstructured":"Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao J-A, Sullivan E, Luke T, Davey RT Jr (2018) Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 18(4):410\u2013418","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4768_CR137","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/171.6.1387","volume":"171","author":"JB Robbins","year":"1995","unstructured":"Robbins JB, Schneerson R, Szu SC (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171(6):1387\u20131398","journal-title":"J Infect Dis"},{"issue":"9","key":"4768_CR138","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","volume":"24","author":"A Casadevall","year":"2003","unstructured":"Casadevall A, Pirofski A (2003) Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol 24(9):474\u2013478","journal-title":"Trends Immunol"},{"issue":"8","key":"4768_CR139","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","volume":"38","author":"A Casadevall","year":"1994","unstructured":"Casadevall A, Scharff MD (1994) Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 38(8):1695","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"4768_CR140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.1932.02740650008003","volume":"99","author":"WH Park","year":"1932","unstructured":"Park WH (1932) Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. J Am Med Assoc 99(13):1050\u20131053","journal-title":"J Am Med Assoc"},{"issue":"8","key":"4768_CR141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jama.1926.02680080022009","volume":"87","author":"WH Park","year":"1926","unstructured":"Park WH, Freeman RG (1926) The prophylactic use of measles convalescent serum. J Am Med Assoc 87(8):556\u2013558","journal-title":"J Am Med Assoc"},{"issue":"5","key":"4768_CR142","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2105\/AJPH.25.5.595","volume":"25","author":"JR Gallagher","year":"1935","unstructured":"Gallagher JR (1935) Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health Nations Health 25(5):595\u2013598","journal-title":"Am J Public Health Nations Health"},{"key":"4768_CR143","doi-asserted-by":"crossref","unstructured":"RAMBAR AC (1946) Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child 71(1):1\u201313","DOI":"10.1001\/archpedi.1946.02020240008001"},{"key":"4768_CR144","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/CCM.0b013e3181d44c1e","volume":"38","author":"TC Luke","year":"2010","unstructured":"Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH (2010) Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66\u2013e73","journal-title":"Crit Care Med"},{"issue":"8","key":"4768_CR145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145(8):599\u2013609","journal-title":"Ann Intern Med"},{"issue":"4","key":"4768_CR146","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"IF Hung","year":"2011","unstructured":"Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, Liu R, Watt C-L, Chan W-M, Lai K-Y (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52(4):447\u2013456","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4768_CR147","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","volume":"74","author":"F Sahr","year":"2017","unstructured":"Sahr F, Ansumana R, Massaquoi T, Idriss B, Sesay F, Lamin J, Baker S, Nicol S, Conton B, Johnson W (2017) Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 74(3):302\u2013309","journal-title":"J Infect"},{"issue":"4","key":"4768_CR148","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","volume":"61","author":"CS Kraft","year":"2015","unstructured":"Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM III, Friedman-Moraco RJ (2015) The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 61(4):496\u2013502","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4768_CR149","first-page":"489","volume":"12","author":"L Kong","year":"2006","unstructured":"Kong L, Zhou B (2006) Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 12(6):489","journal-title":"Hong Kong Med J"},{"issue":"14","key":"4768_CR150","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","volume":"357","author":"B Zhou","year":"2007","unstructured":"Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357(14):1450\u20131451","journal-title":"N Engl J Med"},{"key":"4768_CR151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","volume":"41","author":"X-X Wu","year":"2015","unstructured":"Wu X-X, Gao H-N, Wu H-B, Peng X-M, Ou H-L, Li L-J (2015) Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis 41:3\u20135","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4768_CR152","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, Chan P, Wong K, Leung C, Cheng G (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24(1):44\u201346","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"4768_CR153","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","volume":"56","author":"K-M Yeh","year":"2005","unstructured":"Yeh K-M, Chiueh T-S, Siu L, Lin J-C, Chan PK, Peng M-Y, Wan H-L, Chen J-H, Hu B-S, Perng C-L (2005) Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 56(5):919\u2013922","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4768_CR154","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"J-H Ko","year":"2018","unstructured":"Ko J-H, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, Kim Y-J, Park JK, Chung CR, Kang E-S (2018) Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral Ther 23(7):617\u2013622","journal-title":"Antiviral Ther"},{"issue":"9","key":"4768_CR155","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","volume":"22","author":"YM Arabi","year":"2016","unstructured":"Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F (2016) Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 22(9):1554","journal-title":"Emerg Infect Dis"},{"key":"4768_CR156","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","volume":"10","author":"EA Van Erp","year":"2019","unstructured":"Van Erp EA, Luytjes W, Ferwerda G, Van Kasteren PB (2019) Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol 10:548","journal-title":"Front Immunol"},{"key":"4768_CR157","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3389\/fimmu.2019.02110","volume":"10","author":"JA Jenks","year":"2019","unstructured":"Jenks JA, Goodwin ML, Permar SR (2019) The roles of host and viral antibody Fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity. Front Immunol 10:2110","journal-title":"Front Immunol"},{"key":"4768_CR158","doi-asserted-by":"crossref","unstructured":"Gunn BM, Yu W-H, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K (2018) A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell Host Microbe 24(2):221\u2013233 (e225)","DOI":"10.1016\/j.chom.2018.07.009"},{"key":"4768_CR159","unstructured":"China puts 245 COVID-19 patients on convalescent plasma therapy. https:\/\/www.xinhuanet.com\/english\/2020-02\/28\/c_138828177.htm. Retrieved 12 Apr 2020"},{"issue":"9","key":"4768_CR160","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1164\/rccm.200702-271OC","volume":"176","author":"O Gajic","year":"2007","unstructured":"Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR (2007) Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 176(9):886\u2013891","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4768_CR161","first-page":"E02015","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q et al (2020) Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 94(5):E02015","journal-title":"J Virol"},{"key":"4768_CR162","doi-asserted-by":"crossref","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, Makki S, Rooney KD, Group CPS, Nguyen-Van-Tam JS (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211(1):80\u201390","DOI":"10.1093\/infdis\/jiu396"},{"issue":"7","key":"4768_CR163","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.167.7.3910","volume":"167","author":"JE Crowe","year":"2001","unstructured":"Crowe JE, Firestone C-Y, Murphy BR (2001) Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 167(7):3910\u20133918","journal-title":"J Immunol"},{"key":"4768_CR164","unstructured":"Drugmaker Takeda is working on coronavirus drug. https:\/\/www.wsj.com\/articles\/drugmakertakeda-is-working-on-coronavirusdrug-11583301660. Retrieved 10 Apr 2020"},{"issue":"10","key":"4768_CR165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2105\/AJPH.8.10.741","volume":"8","author":"L McGuire","year":"1918","unstructured":"McGuire L, Redden W (1918) The use of convalescent human serum in influenza pneumonia\u2014a preliminary report. Am J Public Health 8(10):741\u2013744","journal-title":"Am J Public Health"},{"issue":"12","key":"4768_CR166","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkw338","volume":"71","author":"Y Mo","year":"2016","unstructured":"Mo Y, Fisher D (2016) A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother 71(12):3340\u20133350","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"4768_CR167","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J et al (2020) Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323(16):1582\u20131589","journal-title":"JAMA"},{"issue":"10228","key":"4768_CR168","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","volume":"395","author":"RM Anderson","year":"2020","unstructured":"Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (2020) How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 395(10228):931\u2013934","journal-title":"Lancet"},{"issue":"31","key":"4768_CR169","doi-asserted-by":"crossref","first-page":"e21429","DOI":"10.1097\/MD.0000000000021429","volume":"99","author":"B Liang","year":"2020","unstructured":"Liang B, Chen J, Li T, Wu H, Yang W, Li Y et al (2020) Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. Medicine 99(31):e21429","journal-title":"Medicine"},{"issue":"2","key":"4768_CR170","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S (2020) Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11(2):216\u2013228","journal-title":"Aging Dis"},{"issue":"1","key":"4768_CR171","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12865-014-0041-4","volume":"15","author":"RF Foronjy","year":"2014","unstructured":"Foronjy RF, Dabo AJ, Cummins N, Geraghty P (2014) Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol 15(1):41","journal-title":"BMC Immunol"},{"issue":"12","key":"4768_CR172","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.4049\/jimmunol.1200256","volume":"188","author":"LJ Quinton","year":"2012","unstructured":"Quinton LJ, Mizgerd JP, Hilliard KL, Jones MR, Kwon CY, Allen E (2012) Leukemia inhibitory factor signaling is required for lung protection during pneumonia. J Immunol 188(12):6300\u20136308","journal-title":"J Immunol"},{"key":"4768_CR173","doi-asserted-by":"crossref","unstructured":"Metcalfe SM, Strom TB, Williams A, Fahmy TM (2015) Multiple sclerosis and the LIF\/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF. Nanobiomedicine 2(Godi\u0161te 2015):2\u20135","DOI":"10.5772\/60622"},{"key":"4768_CR174","unstructured":"Mesoblast stem cell drugs for novel coronavirus. https:\/\/ipscell.com\/2020\/03\/athersys-mesoblast-stem-cell-drugs-fornovelcoronavirus-covid-19\/. Retrieved 31 Mar 2020"},{"key":"4768_CR175","doi-asserted-by":"crossref","unstructured":"Ulich TR, Fann M-J, Patterson PH, Williams JH, Samal B, Del Castillo J, Yin S, Guo K, Remick DG (1994) Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. Am J Physiol Lung Cell Mol Physiol 267(4):L442\u2013L446","DOI":"10.1152\/ajplung.1994.267.4.L442"},{"issue":"33","key":"4768_CR176","doi-asserted-by":"crossref","first-page":"31226","DOI":"10.1074\/jbc.M301820200","volume":"278","author":"J Wang","year":"2003","unstructured":"Wang J, Chen Q, Corne J, Zhu Z, Lee CG, Bhandari V, Homer RJ, Elias JA (2003) Pulmonary expression of leukemia inhibitory factor induces B cell hyperplasia and confers protection in hyperoxia. J Biol Chem 278(33):31226\u201331232","journal-title":"J Biol Chem"},{"key":"4768_CR177","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.medidd.2020.100019","volume":"5","author":"SM Metcalfe","year":"2020","unstructured":"Metcalfe SM (2020) Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 5:100019","journal-title":"Med Drug Discov"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-020-04768-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:08:05Z","timestamp":1628554085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-020-04768-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":177,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4768"],"URL":"https:\/\/doi.org\/10.1007\/s00705-020-04768-3","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}